Based on the Real-World Results From Australia, Immunotherapy Is Not a Good Option for Patients With Mesothelioma
Steven G. Gray, Tomer Meirson, Luciano Mutti
Topics & Concepts
MedicineNivolumabIpilimumabClinical trialOncologyFood and drug administrationRegimenInternal medicineMesotheliomaImmunotherapyIntensive care medicinePharmacologyPathologyCancerOccupational and environmental lung diseasesPleural and Pulmonary DiseasesInterstitial Lung Diseases and Idiopathic Pulmonary Fibrosis